Nasal High Flow therapy is being widely adopted in neonatal and pediatric practice. The literature supports the early and integrated use of Nasal High Flow therapy to optimize the patient journey.

The impact of a new therapy at the Rosie

Optiflow™ Junior in Practice

The Rosie Hospital is part of Cambridge University Hospitals NHS Foundation Trust, one of the largest and best-known trusts in the United Kingdom. The unit is one of the biggest in the United Kingdom with a 58-cot capacity and is the referral center for the East of England region. Watch this video series to learn about their journey to successfully implementing Nasal High Flow therapy into their Neonatal Intensive Care Unit. 

Health Economic Benefits are Emerging

If a patient is able to avoid escalation of therapy1,2 and has a shorter length of stay3 in an intensive care setting, this may result in overall cost savings to the hospital1.